<DOC>
	<DOCNO>NCT00316212</DOCNO>
	<brief_summary>The purpose trial identify dose dos INS50589 intravenous infusion well-tolerated reduce postoperative bleeding blood product transfusion .</brief_summary>
	<brief_title>Study INS50589 Intravenous Infusion Subjects Undergoing Coronary Artery Bypass Grafting ( CABG ) Involving Cardiopulmonary Bypass</brief_title>
	<detailed_description />
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>INS 50589</mesh_term>
	<criteria>Are schedule primary CABG median sternotomy involve cardiopulmonary bypass Willing receive allogeneic blood product transfusion surgery Have previous cardiac surgery Have previous median sternotomy Have tendency bleed family history bleed Have abnormally low platelet count Have receive certain anticoagulant antiplatelet medication within specified time period prior schedule CABG surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Coronary Artery Bypass Graft Surgery involve Cardiopulmonary Bypass</keyword>
</DOC>